source
- Argenx reports Phase 3 success for Vyvgart Hytrulo in autoimmune myositis, despite subgroup shortfallArgenx announced that its subcutaneous antibody Vyvgart Hytrulo achieved its primary endpoint in a Phase 3 trial for autoimmune myositis, a rare group of inflammatory muscle diseases. The trial de…
- Biotech's reverse merger renaissance poised to continueA biotech collected $820 million in investor commitments this month to take its China-sourced immunology drug onto the public markets. That would make it one of the largest, if not the ...Endpoints · 1h ago↗ source